Biomarker Briefing · February 2026

suPAR: the quiet signal behind chronic inflammation

A biomarker that may outperform CRP for predicting cardiovascular disease, biological aging, and all-cause mortality.

The challenge

Chronic inflammation is the common thread behind the diseases we fear most

Cardiovascular disease Type 2 diabetes Cancer Accelerated aging

But our most common inflammation marker — CRP — only captures acute flare-ups, missing the slow, compounding signal underneath.

01 — What It Is

soluble urokinase Plasminogen Activator Receptor

A protein released into the bloodstream when immune cells are activated. Unlike CRP — which spikes after a bad night's sleep — suPAR reflects the body's cumulative, chronic level of immune activation.

🔬 Backed by 1,000+ peer-reviewed studies · Identified 1991 · EMA + FDA approved
⛅
CRP checks the weather
Spikes with acute illness, fluctuates daily, affected by circadian rhythm. A snapshot of right now — not the trend.
🌎
suPAR reads the climate
Stable across weeks. Unaffected by acute events. Reflects cumulative immune activation — the slow burn that drives long-term disease.
suPAR at a glance

The biomarker in numbers

1,000+
Peer-reviewed studies across clinical and population settings
1991
Year suPAR was first identified as an immune activation biomarker
EMA + FDA
First biomarker approved by both agencies for treatment decisions
Danish
Origin — foundational research from Copenhagen university hospitals
02 — Why It Matters

suPAR vs. traditional markers

Property
CRP
IL-6
suPAR
What it reflects
Acute-phase response
Cytokine signaling
Chronic immune activation
Stability
Low — daily fluctuation
Low — hourly fluctuation
High — stable across weeks
Predicts CVD
Yes
Weakly
Yes — outperforms CRP
Predicts aging
Not established
Weakly
Validated (Dunedin study)
Circadian effect
Moderate
High
Negligible
FDA status
FDA-approved
Research use
Not approved (LDT only)
Cost per test
Low (~$5–15)
Moderate
Higher (~$50–150)
03 — Reference Ranges

What the numbers mean

Measured in ng/mL from a standard blood draw. Based on 9,300+ healthy Danish blood donors.

Low risk < 3.0 ng/mL
Healthy baseline — slower biological aging, lower all-cause mortality
Average 3.0 – 4.0 ng/mL
Typical adult range — lifestyle interventions can lower levels
Elevated 4.0 – 6.0 ng/mL
Increased cardiovascular risk, accelerated aging
High risk > 6.0 ng/mL
Strongly associated with adverse outcomes
04 — Key Research
1.88
Hazard ratio for cardiovascular death & MI — after adjusting for CRP, troponin-T, NT-proBNP, and traditional risk factors.
Scandinavian Cardiovascular Journal · 2020 · n=1,635
The Dunedin Study

Elevated suPAR at age 45 predicted accelerated aging across every organ system

Older facial appearance. Older brain age. Cognitive decline. Reduced physical function. The Moffitt & Caspi study (widely cited) validated suPAR as a biomarker of biological aging pace.

J Gerontol A Biol Sci Med Sci · 2021 · Dunedin cohort · n=~1,000
The good news
4–12 weeks

That's how quickly suPAR responds to lifestyle changes.

🏃
Exercise
🥬
Diet
🚬
Smoking cessation
😴
Sleep quality

suPAR creates a feedback loop: test, change, retest. Consumers don't measure once — they track over time.

05 — Who Offers suPAR Testing

The current testing landscape

Early in consumer adoption — no major US lab or testing platform offers suPAR yet.

Assay Manufacturer

ViroGates

Copenhagen-based manufacturer of the suPARnostic® assay — the leading commercial assay. Spin-out from Copenhagen University Hospital.

DTC — United States

suPAR Health

First US direct-to-consumer suPAR test. At-home blood draw, CLIA-certified lab, ~7 day turnaround with InflammAGE biological age estimate.

DTC — United States

suPARbio

US-based DTC service. Doctor's office or at-home draw, CLIA-certified processing, suPAR concentration + inflammation context.

Growing interest in the longevity, functional medicine, and biohacking communities — but not yet on major platforms like Function Health or Superpower.

06 — Adoption Barriers

Why suPAR hasn't gone mainstream yet

Regulatory

Not FDA-approved

No FDA clearance for general diagnostic use. Labs must run suPAR as a Laboratory Developed Test (LDT) — adding validation burden and regulatory complexity.

Infrastructure

No automated analyzers

Current methods aren't compatible with standard automated platforms, requiring manual workflows and driving per-test costs significantly higher than hsCRP.

Market

hsCRP is entrenched

hsCRP is FDA-approved, runs on every platform, and costs a fraction of suPAR. It's the default — even though it measures something fundamentally different.

ViroGates' TurbiLatex assay format is designed for automated analyzers — the automation gap may close as demand grows.

07 — Bottom Line

suPAR has the research backing. The open questions are regulatory, operational, and commercial.

Who builds the testing infrastructure — and when — will determine how fast it reaches consumers.

artifacts.enchant.co/supar
1 / 13
Contents